Analysed BRIDGEBIO ONCOLOGY THERAPEUT (BBOT:NASDAQ) News Sources
Erasca Stock Is Up 715%. Here’s Why One Biotech Fund Still Bought $68 Million More
17-05-2026
fool.com
Is BridgeBio Oncology Therapeutics, Inc. (BBOT) Stock a Rising Oncology Opportunity With KRAS G12C Therapy Potential?
30-06-2026
yahoo.com
BBOT Reports Second Quarter 2026 Financial Results and Update on Corporate Progress
11-08-2026
yahoo.com
BBOT Presents Preclinical Data Demonstrating pan-KRAS Inhibitor BBO-11818 Has Robust Anti-Tumor Activity in KRAS-Mutant Preclinical Models at the AACR Annual Meeting 2026
22-04-2026
yahoo.com
Here Are Monday’s Top Wall Street Analyst Research Calls: Dell Technologies, BioMarin Pharmaceutical, Disney, HubSpot, Klarna, Oklo, Pitney Bowes, Trade Desk, Wendy’s, and More
11-05-2026
247wallst.com
BBOT Announces New BBO-8520 Data; Highlights Strategic Focus on 2L+ NSCLC BBO-8520 Combination as Well as BBO-11818 and BBO-10203 Combinations in KRAS-Mutant Cancers
08-09-2026
yahoo.com
What is the current price of BRIDGEBIO ONCOLOGY THERAPEUT (BBOT:NASDAQ)?
The current price of BRIDGEBIO ONCOLOGY THERAPEUT (BBOT:NASDAQ) is $2.56.
BRIDGEBIO ONCOLOGY THERAPEUT (BBOT:NASDAQ) absolute price change since previous trading day?
The absolute price change of BRIDGEBIO ONCOLOGY THERAPEUT (BBOT:NASDAQ) since the previous trading day is $-0.08.
BRIDGEBIO ONCOLOGY THERAPEUT (BBOT:NASDAQ) percentage price change since previous trading day?
The percentage price change of BRIDGEBIO ONCOLOGY THERAPEUT (BBOT:NASDAQ) since the previous trading day is -3.0303%.
What is the most recent average sentiment score for BRIDGEBIO ONCOLOGY THERAPEUT (BBOT:NASDAQ)?
The most recent average sentiment score for BRIDGEBIO ONCOLOGY THERAPEUT (BBOT:NASDAQ) is 64 out of 100.
What is the most recent average sentiment for BRIDGEBIO ONCOLOGY THERAPEUT (BBOT:NASDAQ)?
The most recent sentiment for BRIDGEBIO ONCOLOGY THERAPEUT (BBOT:NASDAQ) is .
SEC-8K** Filing Available For BRIDGEBIO ONCOLOGY THERAPEUT (BBOT:NASDAQ)
** material developments that could impact a company's financial condition or stock price.
Author: MattELab
MattELab is the founder and lead developer of SentientMerchant. With a Computer Science and Quantitative Finance background from a T10 university, he brings over 6 years of expertise in NLP, programmatic SEO, and full-stack development to build highly scalable AI and FinTech solutions.